---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048316"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:26:30.630254+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)

## Summary
- Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.
- First $5M tranche received Nov 27, 2024; second $5M due by Jan 31, 2025.
- Proceeds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.
- Juvenescence surrendered 755,728 post-merger warrants; received replacement incentive warrants exercisable at $18.
- Special committee of independent directors approved the related-party transaction.

## SEC filing metadata
- accession: 0001493152-24-048316
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/0001493152-24-048316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048316
- JSON: https://secwatch.observer/filing/0001493152-24-048316.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.